MiR-29b negatively regulates cell cycle activity of human embryonic stem cell-derived cardiomyocytes by Poon, E et al.
Title MiR-29b negatively regulates cell cycle activity of humanembryonic stem cell-derived cardiomyocytes
Author(s) Poon, E; Kong, CW; Yeung, HM; Rushing, SN; Li, YS; Li, RA
Citation
The 16th Medical Resarch Conference (MRC 2011), The
University of Hong Kong, Hong Kong, China, 22 January 2011. In
Hong Kong Medical Journal, 2011, v. 17, suppl. 1, p. 50, abstract
no. 79
Issued Date 2011
URL http://hdl.handle.net/10722/140639
Rights Creative Commons: Attribution 3.0 Hong Kong License
50      Hong Kong Med J Vol 17 No 1 # Supplement 1 # February 2011
XX
XX
MiR-29b negatively regulates cell cycle activity of human embryonic stem cell–derived  
cardiomyocytes
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introduction: Cardiomyocytes (CM) withdraw from the cell cycle when they enter adulthood and mature in terms of 
their electrophysiological and Ca2+ handling properties. However, the mechanisms underlying human CM cell cycle 
exit and maturation are poorly understood. We previously demonstrated that miR-29b is upregulated in human adult 
CM relative to fetal CM and human embryonic stem cells (hESC)–derived CM. Here, we aimed to test our hypothesis 
that miR-29b is important for hESC-CM cell cycle exit and maturation.
Methods: We overexpressed miR-29b in hESC-CM by lentiviral transduction. We then compared the proliferation 
potential of control and miR-29 overexpressing hESC-CM by immunostaining for the presence of Ki67, a proliferation 
marker. The mRNA expression of cyclins and cyclin-dependent kinases were examined by quantitative real-time PCR. 
We also performed functional assays including patch-clamp and Ca2+-imaging to assess the maturation of control and 
miR-29 overexpressing hESC-CM.
Results: MiR-29b overexpression inhibited hESC-CM proliferation by decreasing the mRNA expression of multiple 
cyclins and cyclin-dependent kinases. However, electrophyiological and Ca2+ handling properties were unchanged, 
indicating that hESC-CM maturation was not affected by miR-29b overexpression.
Conclusion: We conclude that miR-29b is a negative regulator of hESC-CM cell cycle, but miR-29b induced cell cycle 
exit does not promote hESC-CM maturation.
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Pharmacological management of obesity in the National Health and Nutrition Examination  
Survey (NHANES) 2007-8
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introduction: Obesity is a growing problem worldwide. We set out to investigate the use of anti-obesity drugs in the 
United States in recent years.
Methods: We included 2630 men and 2702 women who took part in the National Health and Nutrition Examination 
Survey (NHANES) in 2007-8. We analysed their demographic and anthropometric data, and their weight and drug 
history. Sampling weights were used to adjust for non-response bias and the oversampling of blacks, Mexican 
Americans, and the elderly.
Results: 46.0% of men and 44.9% of women were candidates for anti-obesity medication (initial body mass index ≥30 
kg/m2, or ≥27 kg/m2 in the presence of other risk factors [eg hypertension, diabetes or dyslipidemia]). Among these 
participants, 85.1% considered themselves overweight and 90.1% would like to lose weight. However, only 61.9% 
had dietary changes, 36.5% exercised, 3.7% took non-prescription diet pills and 2.2% took prescription diet pills to 
control weight during the preceding year. During the preceding month, 0.4% and 0.1% of participants were taking 
phentermine and orlistat, respectively. There were no participants on sibutramine.
Conclusions: Obesity is highly prevalent in the United States, but only a very small percentage is on anti-obesity 
medication. The withdrawal of sibutramine in October 2010 would have minimal impact on the general population. 
While improvements in pharmacological treatment of obesity are needed, our study revealed that there is also a need 
for more lifestyle changes in the majority of obese individuals.
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